Based on the effect of YTHDF2 on ICC tumourigenesis and desensitisation to cisplatin, we further explored the effect of combination treatment with siYTHDF2 and cisplatin in a chemoresistant PDX model of ICC (PDX0075) from a patient who relapsed in 6 months after R0 resection and subsequent chemotherapy with cisplatin and gemcitabine. The gene discussed is YTHDF2; the disease is intrahepatic cholangiocarcinoma.